

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/004761 A2

(51) International Patent Classification⁷: A61K 39/39

(21) International Application Number: PCT/CA2003/000985

(22) International Filing Date: 30 June 2003 (30.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/393,659 5 July 2002 (05.07.2002) US

(71) Applicants and

(72) Inventors: LECLERC, Denis [CA/CA]; 8 rue des Sapins, Fossambault-sur-le-Lac, Québec G0A 3M0 (CA). MAJEAU, Nathalie [CA/CA]; 8 rue des Sapins, Fossambault-sur-le-lac, Québec G0A 3M0 (CA). TESSIER, Philippe [CA/CA]; 1056 de St-Sébastien, Cap-Rouge, Québec G1Y 2S5 (CA). LÓPEZ-MACÍAS, Constantino III Roberto [MX/MX]; Ejército Nacional #14-103 Col. Anzures, México D.F. 11590 (MX).

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/004761 A2

(54) Title: ADJUVANT VIRAL PARTICLE

(57) Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasitic pathogen may be used as a vaccine.

- 1 -

ADJUVANT VIRAL PARTICLE

TECHNICAL FIELD

The present invention relates to a viral particle bearing immunogens and having immunopotentiation or adjuvant activity. The invention particularly relates
5 to recombinant viral particles and method for enhancing an immune response in a human or an animal by means of these particles.

BACKGROUND ART

Vaccination is the most efficient method to fight against infectious diseases. The appearance of new viral diseases (e.g. Hepatitis C virus, Human
10 immunodeficiency virus), and the resistance of pathogenic bacteria (*Salmonella typhii*) to antibiotics are alarming. Vaccination thus become an efficient alternative to help controlling these diseases.

Over the last past 15 years, genetic engineering allowed the precise identification of protein fragments that are responsible for the protective immune
15 response. Therefore, new vaccination strategies emerged. Immunisation of animals with appropriate immunogenic peptides allowed the production of neutralising antibodies that can control diseases. The expression of those immunogenic peptides in heterologous systems provided the basis of subunit vaccines.

Although it has been demonstrated that chemically synthesised
20 oligopeptides are capable of stimulating the production of antibodies against the protein from which they are derived, the peptides themselves have generally been found to be insufficiently immunogenic to serve as vaccines. This is why there has been considerable interest in developing epitope-presentation systems, in which the peptide sequence is fused to a carrier molecule capable of assembly into a
25 macromolecular structure.

Specific immunity can be enhanced by the use of immunopotentiators, such as adjuvants, when administering an antigen to a host. The immune response

OR File No.15810-1PCT

- 2 -

is mediated by a variety of cells in the immune system. There are two types of immune response: humoral immunity mediated by antibodies, and cellular immunity mediated primarily by cytotoxic T lymphocytes. Antigen presenting cells ("APC") process and present antigen to both B and T cells. B cells secrete specific 5 antibodies as a result of activation and T cells either become helper cells to the humoral response or cytotoxic cells and directly attack the antigen. Adjuvants have been shown to augment these immune responses.

Initial presentation of an antigen induces both IgM and IgG antibodies, forming the primary response. This production of antibodies may fall off, however, 10 over time. A secondary response, which principally involves the production of IgG antibodies, may be triggered by the secondary or later in time presentation of the antigen. A secondary or even primary response, however, is not guaranteed merely by priming the host with an antigen.

A difficulty often encountered in the administration of an antigen is the 15 extent to which the immune system will respond. Certain antigens are not very immunogenic in that upon administration they provoke a weak primary response or no response at all. In such cases, the immune system may not respond to a secondary challenge, and for example, the host may suffer from the disease or condition that the immunization with the antigen was designed to prevent.

20 In such situations, it is common to give a physiological response modulator ("PRM"). A PRM generally is defined as an immunopotentiating compound. It may be derived from bacteria, such as *Bordetella pertussis* or *Corynebacterium parvum*. PRM also may include chemicals, such as polynucleotides, physiologically active molecules, such as thymic hormones, and 25 adjuvants.

Adjuvants are compounds which enhance the immune systems response when administered with antigen producing higher antibody titres and prolonged

OR File No.15810-1PCT

- 3 -

host response. Commonly used adjuvants include Incomplete Freund's Adjuvant, which consists of a water in oil emulsion, Freund's Complete Adjuvant, which comprises the above with the addition of *Mycobacterium tuberculosis*, and alum. The difficulty, however, in using these materials in humans, for example, is that 5 they are toxic or may cause the host to develop lesions at the site of injection.

Another approach was described by Kawamura and Berzofsky in *J. Immunol.*, 136:58 (1986). In this approach, anti-Ig antibodies, which are reactive with immunoglobulins present on certain B cells, were conjugated to ferritin and myoglobin, and were administered to mice with Incomplete Freund's Adjuvant. 10 Immunogenicity of the mixture was improved, but there was no indication of the immunogenicity of the mixture without the addition of the adjuvant. Also, whilst adjuvants such as Freund's complete adjuvant, Freund's incomplete adjuvant and Montanide can greatly enhance the immune response to an antigen, they suffer from some disadvantages. When used with an antigen in an injectable form, large 15 lesions often form at the site of injection, a situation which renders them unsatisfactory for such use in humans, pets or in meat animals. Furthermore, these adjuvants fail to act as immunopotentiating agents when administered orally or enterally.

It is known in the art that carriers of immunogen or antigens of different 20 nature can be relatively easily genetically engineered. Plant virus are those systems that can be produced in plants and are easily adapted to this application. Cowpea mosaic virus (CPMV), tobacco mosaic virus X (TMVX), and alfalfa mosaic virus (AIMV) are known to have been modified for the presentation of epitopes of interest. Another plant viral vector, potato virus X (PVX), a member of the 25 potexvirus group, is known to tolerate carriage of a complete protein overcoat. Also, US Patents 6,232,099 and 6,042,832, International Patent applications published under number WO 97/39134, WO 02/04007, WO 01/66778, WO 02/00169, and EP application 1167530, all describe different variations of virus-

OR File No.15810-1PCT

- 4 -

like particles carrying foreign proteins in fusion with endogenous proteins. However, nowhere in these references it is mentioned that such particles have any immunopotentiation or adjuvant properties.

Considering the state of the art described herein, there is still a great need 5 for compounds and carrier particles allowing a strong immunization of human and animals while avoiding the use of adjuvants and second vaccinations as actually practiced.

DISCLOSURE OF THE INVENTION

One aim of the present invention is to provide an immunogen-carrier 10 complex having an immupotentiation property, consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP, that may be used in the preparation of a composition for inducing an immune response against the protein or fragment thereof..

Another aim of the present invention is to provide a composition 15 comprising a viral-like particle (VLP) and a protein or an extract derived from a virus, bacteria or parasite, that may be used as a vaccine.

In accordance with the present invention there is also provided a method 20 for immunopotentiating an immune response in a human or an animal which comprises administering to said human or animal an immunogen-carrier consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP, or administering a VLP or a fragment thereof concomitantly with an antigen not directly linked to said VLP.

The present invention also relates to polynucleotide encoding a 25 immunogen-carrier complex consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or A polynucleotide encoding a immunogen-carrier complex consisting of a fragment thereof of said VLP, or a

OR File No.15810-1PCT

- 5 -

VLP alone, said immunogen-carrier complex having the capacity of being assembled when expressed in a plant cell, an animal cell or a microorganism.

The invention also provides for the use of a papaya mosaic virus as an adjuvant.

5 For the purpose of the present invention the following terms are defined below.

10 The expression "chimeric protein" is created when two or more genes that normally code for two separate proteins recombine, either naturally or as the result of human intervention, to code for a protein that is a combination of all or part of each of those two proteins.

The expression "fusion capsid protein" means a fusion protein in which one of the genes in the fusion codes for a plant virus capsid protein.

15 The expression "protective immunity" as used herein is intended to mean the ability of an animal, such as a mammal, bird, or fish, to resist (delayed onset of symptoms or reduced severity of symptoms), as a result of its exposure to the antigen of a pathogen, disease or death that otherwise follows contact with the pathogen. Protective immunity is achieved by one or more of the following mechanisms: mucosal, humoral, or cellular immunity. Mucosal immunity is primarily the result of secretory IgA (sIgA) antibodies on mucosal surfaces of the 20 respiratory, gastrointestinal, and genitourinary tracts. The sIgA antibodies are generated after a series of events mediated by antigen-processing cells, B and T lymphocytes, that result in sIgA production by B lymphocytes on mucosa-lined tissues of the body. Mucosal immunity can be stimulated by an oral vaccine. The primary result of protective immunity is the destruction of the pathogen or 25 inhibition of its ability to replicate itself.

The expression "humoral immunity" as used herein means the result of IgG antibodies and IgM antibodies in serum.

OR File No.15810-1PCT

- 6 -

The expression "cellular immunity" as used herein can be achieved through cytotoxic T lymphocytes or through delayed-type hypersensitivity that involves macrophages and T lymphocytes, as well as other mechanisms involving T cells without a requirement for antibodies.

5 A "recombinant virus" is one in which the genetic material of a virus has combined with other genetic material.

The terms "polypeptide" or "peptide" as used herein is intended to mean a molecule in which there is at least four amino acids linked by peptide bonds.

10 The expression "viral nucleic acid" as used herein may be the genome (or a majority thereof) of a virus, or a nucleic acid molecule complementary in base sequence to that genome. A DNA molecule that is complementary to viral RNA is also considered viral nucleic acid. An RNA molecule that is complementary in base sequence to viral DNA is also considered to be viral nucleic acid.

15 The term "virus-like particle" (VLP) as used herein refers to self-assembling particles which have a similar physical appearance to virus particles and includes pseudoviruses. Virus-like particles may lack or possess dysfunctional copies of certain genes of the wild-type virus, and this may result in the virus-like-particle being incapable of some function which is characteristic of the wild-type virus, such as replication and/or cell-cell movement.

20 The term "vaccine" as used herein is intended to mean the fusion protein, any particle of which that protein is a part, or any preparation such as plant material of which that protein is a part.

25 The term "immunopotentiator" as used herein is intended to mean a substance that, when mixed with an antigen, enhances immunogenicity or antigenicity and provides a superior immune response. It will be recognized that it can enhance the expression of co-stimulators on macrophages and other antigen-presenting cells.

OR File No.15810-1PCT

- 7 -

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates an electron micrograph of purified PapMV;

Figs. 2 illustrate tricine SDS-PAGE analysis of the PapMV CP(A) and
5 immunogold labeling showing that the fusion is exposed at the surface of the
PapMV VLP (B);

Figs. 3A to 3G illustrate electron micrographs of PapMV and PapMV
VLP assembled *in vitro*;

Fig. 4 illustrates the leukocyte accumulation induced by PapMV in the
10 air pouch model;

Fig. 5 illustrates the immune response to PapMV. Mice (6 for each
concentration) that were injected IP once with PapMV or with ISS (Isotonic saline
solution;

Fig. 6 illustrates an immune response to PapMV. Mice (6 for each
15 concentration) that were injected IP once with PapMV or with ISS (Isotonic saline
solution;

Fig. 7 illustrates an evaluation of the PapMV potency as adjuvant to
ovabulmin;

Figs. 8 A and 8B illustrate the characterization of the immune response
20 to the PapMV and to HCV peptides derived from the HCV surface glycoprotein's
E1 and E2; and

Fig. 9 illustrates Western blotting showing the specific migration of the
PapMV CP to lymph node and spleen with an intraperitoneal injection.

METHOD OF CARRYING OUT THE INVENTION

In accordance with the present invention, there is provided a virus-like particle carrying immunogen in fusion with endogenous viral proteins, therefore forming a new type of immunogen-carrier being also capable of 5 immunopotentiation or having an adjuvant effect.

In one embodiment of the present invention, there is provided a class of carriers which when linked genetically to an immunogen or hapten can enhance the host's immune response to the immunogen or hapten regardless of whether the complex is administered parenterally, enterally or orally. In addition their use does 10 not result in the formation of large lesions at injection sites.

Accessory cells such as macrophages, B lymphocytes, and dendritic cells are essential for the induction of T cell-dependent immune responses. Accessory cells present antigens to MHC-restricted T cells and produce membrane-associated and secreted costimulators that enhance the proliferation and differentiation of T 15 lymphocytes. Therefore, the presence of competent accessory cells stimulates T cell-dependent immune responses, and their absence leads to deficient responses. Resting macrophages and naïve, unstimulated B lymphocytes sented by such antigen-presenting cells (APCs) may fail to stimulate naïve CD4+ T cells, and may even induce T cell tolerance. In contrast, dendritic cells and activated macrophages 20 and B cells do express costimulators, as well as high levels of APCs. A mechanism of action of the immunogen-carrier of the present invention, is to enhance the expression of costimulators on macrophages and other APCs. Because of this, the administration of immunogens or protein antigens with the immunogen carriers of the invention, acting simultaneously as an adjuvant, promotes cell-mediated 25 immunity and T cell-dependent antibody production. Immunogens are most effective for generating systemic immunity when administered coupled together with an immunogen-carrier of the present invention.

In a first embodiment, the invention provides a complex comprising an immunogen coupled to a carrier virus-like particle (VLP), such that the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to said host, wherein the immunogen may 5 comprise either an antigen or a hapten and the carrier molecule comprises an integral particle of a virus. More particularly, the virus of the present invention is a plant virus.

One way to obtain a good response of B cells is to present the antigen in an organized manner. It is shown that repetitively arranged epitopes cross-link to B 10 cell receptor efficiently and induce a prompt T-independent IgM response followed later by an IgG response. Therefore, a good strategy to increase the immunogenicity of the epitopes and the recognition and presentation to the immune system is the expression of the immunodominant epitopes in an organized fashion like on the surface of a plant virus like PapMV. Particularly, PapMV fulfils several 15 characteristics of a good adjuvant and carrier because it is a phylogenetically distant antigen, it is exogenous to the mammal immune system, it is molecularly very complex and it is an organized structure that has a high molecular weight.

It has been surprisingly recognized by the applicant that a crystalline and repetitive structure is not only recognised by the innate immune system, but has in 20 addition an adjuvant effect on the immune system of an immunized host.

In one embodiment of the present invention, there is provided a method in which the use of benign high copy number rod-shaped viruses, preferably plant viruses such as papaya mosaic virus (PapMV), produce immunogen connected to viral coat protein subunits. When assembled, the virus particles comprise long 25 helical arrays of more than 1000 identical fusion proteins (which are typically coat protein--foreign protein fusion molecules) per virion. Generally, the immunogen portion will be displayed on the outer surface of the virus particles.

OR File No.15810-1PCT

- 10 -

According to the present invention, the structure of the capsid proteins of plant and animal viruses fulfil these requirements and can be engineered to present immunogenic peptides derived from the pathogen or other sources with which a vaccine-adjuvant is produced. The coat protein of papaya mosaic virus (PapMV), 5 for example, but without limiting it thereto, is an excellent candidate for the development of such a immunogen-carrier-immunopotentiator. This virus harbours a crystalline rod shape and is very repetitive (1200 copies of the same subunit per virion). Recent immunization experiments with PapMV indicate that this virus induces a very strong immune response in mice and is an excellent vector for the 10 development of a vaccine. This immunogen carrier virus can be engineered with several immunogenic peptides of the HCV surface envelope proteins, such as for example, *Salmonella typhii* peptides derived from the porin protein, and with the peptide α 9-23 of insulin. The assembly of fusion coat proteins carried by virus like particles (VLPs) are defined as an immunogen-carrier having adjuvant or 15 immunopotentiating properties.

According to the present invention, it is possible to immunopotentiate, or boost an immune reaction against a given antigen. It is known particularly that small molecules often act only poorly as immunogens in their ability to elicit antibodies in an *in vivo* system. When attached to a immunogen-carrier virus of the 20 present invention, that itself is antigenic, it will give rise to improved antibody response to the smaller molecule. The small molecule attached to the immunogen-carrier in this system, may be called a hapten or antigen, and can vary in size from small to quite large. In one example of this combination, of interest to the health care field, a small portion of the Hepatitis B surface antigen, comprising a sequence 25 of determined amino acids, which is not itself antigenic, can be covalently bound to the VLP, keyhole limpet immunogen-carrier, and the resulting conjugate elicits antibodies in an *in vivo* system that may cross-react with the native surface antigen of the VLP and also strongly with the whole hepatitis virus. This system of

OR File No.15810-1PCT

- 11 -

immunogen-carrier can be the basis for an effective vaccine against a disease for which the hapten or antigen codes.

In the present invention, there are provided certain novel immunogen-carriers, as described below, which are conveniently produced by recombinant 5 DNA techniques, which are useful in providing univalent as well as multivalent immunogenic vaccines, and which employ the immunogen-carrier concept described above.

An immunogen is coupled to a carrier VLP to form an immunogen-carrier complex and may then be used in a host in order to provoke an immune 10 response. The immunogen may be specific or recognised for surface structures on T cells, B cells, NK cells and macrophages but not for Class I or Class II APC associated cell surface structures.

The immunogen to which the carrier VLP is coupled may comprise peptides, haptens, carbohydrates, proteins, nucleic acids, and part of viruses, 15 bacteria, parasites and other whole microorganisms. Regardless of the immunogen selected, it must be coupled to the carrier VLP in such a way as not to interfere with the recognition of the immunogen by the host's immune system as an antigenic entity.

The immunogen-carrier complex may be used as a vaccine to raise an 20 immune response in the host. The complex initially may be given in an appropriate dosage in order to elicit an immune response. This may be followed by boosting with the complex or immunogen alone. A variation of this approach may include the formation of one or more immunogen-carrier complexes wherein one or more forms of an immunogen are coupled to one or more carrier VLPs and a plurality of 25 such complexes is administered.

The purpose of administering the immunogen-carrier complex is to provide protection to the host in the form of immunity to the antigen and to avoid

OR File No.15810-1PCT

- 12 -

the use of adjuvants which have undesired side affects.

In one embodiment, the antigen may be as small an immunogen as a hapten or may be relatively large, such as part of a virus. The size and type of antigen is not critical to the practice of this invention. Any antigen may be used for 5 which an immune response is desired in a host. The invention is especially useful, however, for small weakly immunogenic haptens.

Once the immunogen-carrier complex or complexes are formed, the complex or complexes may be administered to the host. The administration regime need not differ from any other generally accepted vaccination programs. A single 10 administration in an amount sufficient to elicit an effective immune response may be used. Alternatively, other regimes of initial administration of the complex followed by boosting with antigen alone or one or more complexes may be used. Similarly, boosting with either the complex or antigen may occur at times that take place well after the initial administration if antibody titres fall below acceptable 15 levels.

A further embodiment of the present invention is that as the VLPs have a regular multivalent and true helical structure which can be more immunogenic than aggregation of protein or free subunits of proteins, it can be easily assembled from an encoding nucleic acid. Also the greater stability of the particle can provide a 20 long lasting exposure of the immunogen portion to the immune system.

The virus portion on which the immunogen is attached, is preferably disposed on the outer surface of the VLP. Thus where the particle is derived from PapMV, the carrier's portion can be disposed on the amino or carboxy terminus, or inserted in an internal loop disposed on the outer surface of the CP. This can result 25 in improved assembly as compared with the assembly of particles having a second portion on another location of the CP, and can enhance immune recognition of the second portion on the particle surface.

OR File No.15810-1PCT

- 13 -

In one embodiment of the present invention, the development of peptide vaccines using a plant viral vector allows to mass- produce vaccines under safe conditions. As much as 1 gram of recombinant virus per kilogram of fresh infected leaves is expected with the recombinant PapMV.

5 In another embodiment of the present invention, the administration of 200 μ g of recombinant virus, or immunogen-carrier complex, which corresponds to 14 μ g of peptide, can be sufficient for immunization. One hectare of infected papaya can then potentially be sufficient for the vaccination of 5 million patients. Furthermore, to grow plants is cheap and efficient. Agriculture is the cheapest way
10 to produce a biomass because it does not necessitate sophisticated equipment.

The virus or pseudovirus can be assembled in the host cell to produce infective virus particles which comprise nucleic acid and fusion protein. This can enable the infection of adjacent cells by the infective virus or pseudovirus particle and expression of the fusion protein therein.

15 The host cell can be infected initially with virus or pseudovirus in particle form (i.e. in assembled rods comprising nucleic acid and a protein) or alternatively in nucleic acid form (ie RNA such as viral RNA; cDNA or run-off transcripts prepared from cDNA) provided that the virus nucleic acid used for initial infection can replicate and cause production of whole virus particles having
20 the chimeric protein.

The first (viral) portion of the fusion protein may be any protein, polypeptide or parts thereof, derived from a viral source including any genetically modified versions thereof (such as deletions, insertions, amino acid replacements and the like). In certain embodiments, the first portion will be derived from a viral
25 coat protein (or a genetically modified version thereof). Mention may be made of the coat protein of Papaya Mosaic virus as being suitable for this purpose. A fusion protein molecule can assemble with other fusion protein molecules or with wild-

OR File No.15810-1PCT

- 14 -

type coat protein into a immunogen-carrier virion.

In a preferred embodiment of the invention, the particle is derived from a potyvirus or even more preferably a potexvirus such as PapMV, and in such an embodiment, the second portion is preferably disposed at or adjacent the C-5 terminus of the coat protein. In PapMV, the C-terminus of the coat protein forms a domain on the outside of the virion.

Preferably, a polynucleotide coding for the immunogen portion is inserted at or adjacent a terminus of the polynucleotide coding for the viral portion, such that upon translation, the fusion protein has the viral portion at one end and 10 the immunogen portion at the opposite end. It is not necessary for the viral portion to comprise a whole virus coat protein, but this remains an alternative choice.

A virus or pseudovirus genetically modified to express the fusion protein forms a further embodiment of the present invention, as does any host cell infected with such a virus or pseudovirus.

15 Preferably, the host cell used to replicate the virus or pseudovirus is a bacteria, where the virus is a plant virus, although plant cells, insect cells, mammalian cells and bacteria can be used with viruses which will replicate in such cells. The cell is preferably a bacterium such as *E. coli* although other forms of bacteria and other cells may be useful, such as cells mentioned above. The cell may 20 be a natural host cell for the virus from which the virus-like particle is derived, but this is not necessary.

According to a particular embodiment of the present invention, the whole virus-like particle is used for stable and long lasting presentation of peptide epitopes for the vaccination of animals.

25 According to another embodiment of the present invention, PapMV and PapMV virus like particles appear to be very stable and can be stored easily at room temperature. They resist very high temperature and adverse conditions since

OR File No.15810-1PCT

- 15 -

plant viruses has evolved to resist very difficult conditions that we find in the environment. This is a very important advantage when the vaccine must reach people that are living in poor countries, in regions where access is difficult or for the storage of a diagnostic test for a long period.

5 Alternatively, the VLP described herein can be used alone as immunopotentiator or adjuvant to enhance an immune response in humans or animals against targeted antigens. It is preferable that the adjuvant or immunopotentiating VLP be administered concomitantly with the antigen against which an immune response must be raised. However, the adjuvant VLP can be
10 administered previously or subsequently to, depending on the needs, the administration of the antigen to patients, humans or animals.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

15

EXAMPLE I

Preparation of immunogen-carrier VLP

The avidity of the affinity peptides selected from the panning process
20 described herein will be improved by multimerisation of the peptides. The multimerisation will be done at the surface of papaya mosaic virus (PapMV) that is a member of the potexvirus group. PapMV has a rod-like structure that is made by assembly of the CP subunits. One virus particle contains 1200 subunits. We will make a fusion of the selected peptide with the PapMV CP. The fusion will be made
25 to expose the peptide to the surface of the PapMV particles after *in vitro* assembly from a PapMV CP expressed and purified from an *E.coli* expression system. The

OR File No.15810-1PCT

- 16 -

assembly of the viral CP then ensured multimerisation of the peptide and has considerably improved avidity.

Coat protein (CP) gene was cloned and developed an *in vitro* assembly system using the coat protein (CP) of papaya mosaic virus (PapMV) (Fig. 1). The 5 CP of PapMV was produced in *E.coli* in large amount (Fig.2a) and produced *in vitro* PapMV virus-like particles that are very similar to the wt virus (Fig.2b). It is shown for the first time that a recombinant PapMV CP can assemble in virus-like particles *in vitro*. Fusion of several peptides to the C-terminus of the CP is allowed by assembly *in vitro* and gives rise to virus-like particles that are wider than the wt 10 virus because of the fusion (Fig. 3).

EXAMPLE II

Immunopotentiation effect of immunogen-carrier VLP

An adjuvant is often used in order to increase the immune response of a 15 candidate vaccine. The enhancement of the inflammatory response favours the migration of more phagocytes to the injection site which, in turn results in an improved antigen presentation by antigen-presenting cells (APC). Allun, emulsions, microparticles and cytokines such as GM-CSF have all been used to increase the immune response of the candidate vaccine. It was confirmed that 20 PapMV induced by itself an inflammatory episode, thus eliminating the need for additional adjuvants. The air pouch model was used to examine whether PapMV induced a proinflammatory event *in vivo*. In this model, sterile air is injected under the dorsum of mice at days 0 and 3. At day 7, proinflammatory agents can be injected into the air pouch and the inflammatory response measured. This model 25 closely represents subcutaneous injection sites.

Injection of PapMV into the murine air pouch resulted in the accumulation of approximately 8.5×10^6 leukocytes, compared to 0.8×10^6

OR File No.15810-1PCT

- 17 -

leukocytes in vehicle-injected mice (PBS) (Fig. 4). Neutrophils (85%) and monocytes (15%) accumulated in the air pouch 6 hours after injection of PapMV. While quantities as low as 1 μ g of PapMV were sufficient to induce the accumulation of leukocytes, maximal accumulation occurred when 100 μ g of 5 PapMV was injected. This accumulation was similar to the one induced by injection of 1 μ g of LPS, a powerful proinflammatory factor. These results clearly demonstrate that PapMV can efficiently induce an inflammatory episode. This observation shows clearly that the PapMV is perceived by the immune system which, induces signalling and recruitment of cells involved in the defence of our 10 organism. It is likely that PapMV induces signalling through innate immunity.

Furthermore, it was shown in the present experiment that PapMV induces a strong and long lasting humoral response in mice (Fig. 5). 10 mice were injected with three concentrations of PapMV; 1, 10 and 100 μ g. Primary antibody response in BALB/c mice immunised with PapMV was efficiently induced 15 independently of the route of immunisation (Fig. 5). High titres were detected at day 5 after immunisation. A classic curve of a primary IgM response was observed. Around day 20, IgM response was absent, even after boosting mice with more viruses. IgG response in immunised mice follows a classic kinetics. High titers of anti-PapMV were detected at day 12 after immunisation and proportionally 20 increased after boosting with this virus. Analysis of IgG isotypes showed a preference in the production of IgG2b and IgG1 during the primary and secondary phase of the Ab response. IgG3 increased titres during the memory phase of the ab response. These data shows that PapMV is able to induce an efficient Ab response in mice. Primary and secondary responses were efficiently induced as well as a 25 long lasting Ab memory. The preferential production of IgG1 suggests a preferential release of IL-4. IL-4 favours class switching to this kind of IgG. Therefore a balance towards TH2 response could be envisaged in these mice. The lack on IgG2a indicates the absence of IFN- α release, since this cytokine has been

OR File No.15810-1PCT

- 18 -

involved directly in class switching towards this IgG isotype. Taken together, these data showed the capacity of PapMV to induce an efficient and long lasting antibody response. This result suggests that PapMV particles are excellent vector for the development of a humoral vaccine. The fusion of an immunogen of interest to the 5 VLP will then be recognised as well by the immune system and trigger a strong immune response to the epitope of interest.

Also, it was found that PapMV VLPs migrate specifically to the lymph nodes and the spleen after intraperitoneal or subcutaneous injection in Balb/C mice (Fig. 6). This result indicates that PapMV VLPs are excellent carriers because they 10 migrate efficiently to the sites of emergence of the immune response.

Experimental data demonstrate that the PapMV-antigen induces an efficient antibody response in mice (Fig. 5). In fact, primary and secondary responses are efficiently induced as well as a long lasting antibody memory (Fig. 6). Several immunization routes produced efficiently large amounts of antibodies. 15 Only oral immunization did not result in an immune response. It is likely that the NaHCO₃ used to neutralize the acid of the stomach damaged the virus particles and affected the immunogenicity of the particles. IgG1, IgG2a, IgG2b and IgG3 were present even 350 days after one injection of 100µg of PapMV (Fig. 6). Because 20 IgG2a and IgG3 are present and persist, we can deduce that a TH1 response is induced with PapMV. This suggests that PapMV particles are excellent vectors for the development of an immune humoral response to a foreign antigen. The fusion of an epitope of interest to the PapMV-particle should help to trigger a humoral immune response against the epitope of interest.

Experimental data using the air pouch model in mice dorsum 25 demonstrated that PapMV enhances the inflammatory response and favors the migration of phagocytes to the inoculation site (Fig. 6). This result confirms that PapMV induces by itself an inflammatory episode, thus eliminating the need for

OR File No.15810-1PCT

- 19 -

additional adjuvant strategies aiming at improving antigen presentation by antigen-presenting cells. Similar results were obtained with virus-like particles (VLPs) harboring the fusion of specific peptides generated *in vitro* from recombinant proteins (Fig. 6). The recruitment was very fast since we observed the maximum of 5 cells between 6 to 9 hours after the treatment (data not shown). Furthermore, PapMV-particles are efficient to induce an immune response to ovalbumin, a protein known to be non-immunogenic (Fig. 7). This was established by injecting mice (Balb/C) by intraperitoneal route with 2 mg of Ovabulmin, a protein known to be a very weak immunogen, or in combination with 50 or 100 µg of PapMV. We 10 injected 6 mice per treatment and collected samples at 0, 4, 8, 12 and 20 days after the injection. Only one injection was made for each treatment. We detected a two times stronger immune response to ovalbumine in presence of PapMV even if ovalbumine is a weak immunogen.

These observations demonstrate that PapMV-particles are rapidly 15 perceived as foreign by the mammalian immune system, which in turn induces signaling and recruitment of cells involved in the defense of the organism.

EXAMPLE III

Hepatitis C virus as Vaccination target

20 Hepatitis C virus (HCV) is a plus strand RNA virus that causes acute and chronic liver diseases. The acute phase of infection is generally associated with mild symptoms but it can lead to cirrhosis and hepatocellular carcinoma. More than 170 million people worldwide are infected, which is 4 times as many as for HIV. In the next few years, the number of deaths from HCV associated diseases may even 25 surpass the death rate caused by AIDS. At the present time, current therapies against HCV are unsatisfactory. The only available therapy is interferon (IFN), but

OR File No.15810-1PCT

- 20 -

most HCV are resistant because of an inhibition of the interferon inducible protein kinase (PKR) by HCV E2 protein.

It is known that 20% of infected HCV patients naturally clear the virus. This observation suggests that the immune system can eliminate the viruses if it 5 reacts efficiently. It also suggests that we could help the chronically infected patients if we boost their immune system with a therapeutic vaccine against HCV that could help to clear the viral infection by raising neutralizing antibodies to the virus.

The 2 epitopes chosen are found at the surface of the HCV virion. The 10 E1 epitope (amino acid 285-303) and E2 epitope (amino acids 512-536), are shown to be strongly immunogenic in patients that have cleared the viral infection (David et al., 2001). PapMV was engineered to harbour at its C-terminus the fusion of the E1 and E2 peptide of HCV which, can assemble in PapMV virus like particles *in vitro* (Fig. 3).

15 Three epitopes that are found at the surface of the HCV virion of E1 and E2 outside of HVR-1 in conserved region of the viral envelope glycoproteins were chosen. An E1 epitope (amino acid 285-303) and 2 E2 epitopes (amino acids 512-536 and 528-546) were shown to be strongly immunogenic in patients that have cleared the viral infection. Furthermore, one E2 epitope (512-536) was shown to 20 trigger the production of neutralizing antibodies that are found in the sera of patient that cleared the infection. These three regions are good candidates for the development of a HCV vaccine because they are conserved through HCV subtypes and strains and are located outside the hypervariable region of the envelope glycoproteins. The constructs PapMV-E1 and PapMV-E2 were expressed in *E.coli*. 25 The recombinant proteins were purified and assembled *in vitro*. The assembly of the recombinant CP with the HCV E2 fusions generate rVLPs that are similar to the

OR File No.15810-1PCT

- 21 -

recombinant wt CP control except that they appear to be slightly larger because of the fusion.

Mice were immunized with the recombinant VLPs that were produced *in vitro*. LPS were removed using a polymixin column and injected in mice 5 intraperitoneally and sub-cutaneously. We used 1, 10 and 100 μ g of VLPs and three mice were injected for each treatment. The immune response to the peptide and to the PapMV was analysed by ELISA. It was observed that IgG were directed to the peptide as well as to the surface of the VLPs (Fig. 8). This result shows that recombinant PapMV can be used to trigger an excellent immune response at the 10 surface of epitopes and used as vaccine without the help of adjuvant.

EXAMPLE IV

Immunization against typhoid

Typhoid fever is an acute infection of the reticuloendothelial system, the 15 intestinal lymphoid tissue and gall bladder that is caused by the bacteria *Salmonella typhii*. It is still worldwide a significant disease that affects more than 16 million persons from which, 600,000 do not survive to the infection. The majority of the infection affects children and young adults, and can be prevented by vaccination. Different types of vaccine are currently available: 1) Heat-inactivated, phenol-20 preserved whole-cell parental vaccine (Wyet-Ayerst) administrated intramuscularly or subcutaneously. 2) Acetone-inactivated and dried whole-cell parental vaccine. 3) Purified (non denatured) Vi polysaccharide parental vaccine (Aventis) that is administrated by injection into the deltoid. 4) Attenuated gal E, Vi-negative strain Ty21a, used as a live oral vaccine.

25 Inactivated parental bacteria (type 1-3) can lead to undesired immune responses because of the complexity of the lipopolysaccharide (LPS) and the number of presented antigens that elicit undesirable side effects. Furthermore, the

OR File No.15810-1PCT

- 22 -

Vi polysaccharides are thymus independent antigens (Robins and Robins, 1984) which were shown to have a good efficacy in the field trials but, are also known to be inefficient in inducing immunological memory. Several exposures to the antigen are needed to maintain the protection, making this approach appropriate only for 5 travellers visiting endemic areas. The vaccines currently available are not adapted for people living permanently in contaminated areas. Vaccine based on attenuated bacteria (type 4) can cause nausea, vomiting and abdominal pain. It is also not recommended to administrate this vaccine to patients suffering from immunosuppression, intestinal diseases, diarrhea, taking antibiotics or to pregnant 10 women and children less than 6 years old. This vaccine must be stored at 4°C because it is sensitive to heat and should not be frozen. The sensitivity of ty21A to adverse conditions is problematic when you want to reach populations that live in poor countries under tropical climate which, are the regions most affected by typhoid.

15 A membrane protein from *S. typhii* called porin was shown to be a good immunogen because it elicits both antibody and cellular immune response in mice and humans and was able to protect mice against *S. typhi*. Porins are the most abundant protein on the membrane of Gram-negative bacteria that functions as passive diffusion channels for low molecular weight molecule. These proteins 20 display a high degree of both structural and functional homology, and are therefore assumed to have a common ancestor. Two small epitopes corresponding to loop 6 and 7 of the *S. typhii* porin that are exposed to the surface of the bacteria were shown to be involved in protective mechanisms elicited by immunization with porins. Those regions are specific for *S.typhii* and are excellent epitope for the 25 development of a recombinant subunit vaccine. We have cloned at the C-terminus of the PapMV CP loop 6 of the porin of *S. typhii*. The recombinant protein was purified and the PapMV virus like particles were produced *in vitro* with RNA as described before (Fig. 3F).

OR File No.15810-1PCT

- 23 -

It is understood that the invention is not restricted to the above preferred embodiments, and that modifications are possible provided they are within the scope of the appended claims.

OR File No.15810-1US

- 24 -

WE CLAIM:

1. An immunogen-carrier complex having an immupotentiation property, consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP.
2. The immunogen-carrier complex of claim 1, wherein said immupotentiation property is at least one of an adjuvant effect, a capacity to enhance cell-mediated dependent antibody production or T-cell dependent antibody production, or the capacity of enhancing the expression of at least one costimulator on magrophages or other antigen presenting cells.
3. The immunogen-carrier complex of claim 1, wherein said immunogen is selected from the group consisting of a peptide, a protein, an hapten, and an allergen.
4. The immunogen-carrier complex of claim 1, wherein said immunogen is a viral, a bacterial, or a parasitical protein or fraction thereof capable of inducing an immune response in a human or an animal.
5. The immunogen-carrier complex of claim 1, wherein said immunogen is in carboxy- or amino-terminal fusion with a capsid, coque, or membrane protein of said VLP.
6. The immunogen-carrier of claim 1, wherein said VLP is a virus, a virus particle, a virion or a particle derived from assembly of a viral coat protein.

OR File No.15810-1PCT

- 25 -

7. The immunogen-carrier complex of claim 1, wherein said VLP is selected from the group consisting or a plant potexvirus.

8. The immunogen-carrier complex of claim 7, wherein said potexvirus is a papaya mosaic virus.

9. The immunogen-carrier complex of claim 1, wherein said immunogen is in fusion at the outer surface of said VLP.

10. The immunogen-carrier complex of claim 1, wherein said immunogen is composed of one or more antigen domain, each antigen domain triggering a specific immune response.

11. The immunogen-carrier complex of claim 1, wherein said VLP is carrying immunogens having more than one specificity.

12. A method for immunopotentiating an immune response in a human or an animal which comprises administering to said human or animal an immunogen-carrier consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP, or administering a VLP or a fragment thereof concomitantly with an antigen not directly linked to said VLP.

13. A polynucleotide encoding a immunogen-carrier complex consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or A polynucleotide encoding a immunogen-carrier complex consisting of a fragment thereof of said VLP, or a VLP alone, said immunogen-carrier complex

OR File No.15810-1PCT

- 26 -

having the capacity of being assembled when expressed in a plant cell, an animal cell or a microorganism.

14. Use of a VLP or an immunogen-carrier complex consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP in the preparation of a composition for inducing an immune response against said protein or fragment thereof.

15. A composition for immunopotentiating an immune response against an antigen comprising VLP or an immunogen-carrier complex consisting of a viral-like particle (VLP) carrying at least one immunogen in fusion with a protein or fragment thereof of said VLP.

16. An immunopotentiator comprising VLP or a fragment thereof.

17. A composition comprising a viral-like particle (VLP) and a protein or an extract derived from a virus, bacteria or parasite.

18. The composition according to claim 17, for use as a vaccine.

19. Use of a papaya mosaic virus as an adjuvant.

1/9





Fig. 1

2/9

A

M 1 2 3 4 5 6 7 8 9 10



B




Fig. 2

3/9




Fig. 3

4/9




Fig. 4

5/9




Fig. 5

6/9




Fig. 6

7/9





Fig. 7

8/9

A



B




Fig. 8

9/9

1 2 3 4 5




Fig. 9